|
Allergan said revenue from its U.S. brands rose 38 percent to
about $2.5 billion in the quarter ended Dec. 31, accounting for
58.7 percent of the total revenue.
The Dublin-based company posted a net loss of $700.5 million, or
$1.78 per share, compared with a loss of $732.9 million, or
$3.34 per share.
GAAP results were impacted by acquisition-related expenses, the
company said.
Excluding special items, Allergan earned $3.41 per share, while
analysts were expecting a profit of $3.34 per share, according
to Thomson Reuters I/B/E/S.
Revenue rose about 74 percent to $4.20 billion in the quarter,
beating analysts' average estimate of $4.19 billion.
The company also issued 2016 adjusted revenue forecast of about
$17 billion, slightly shy of the analysts' average estimate of
$17.66 billion.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak
Dasgupta)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
